

Table of Contents

Chapter	Description	Pages
Certificate		i
Declaration		ii
Abstract		iii-iv
Acknowledgment		v-vi
List of tables		vii
List of figures		viii
List of appendices		ix
CHAPTER 1	Introduction	1-37
CHAPTER 2	Review of Literature	38-109
2.1	Polyherbal formulations for diabetes	38
2.2	In vitro analyses	38
2.3	Preclinical trials	38-86
2.4	Clinical trials	86-89
2.5	Plants used in polyherbal formulations for diabetes	89-107
2.6	Additional ingredients of PHF-PHF _s other than the plants	107-108
2.7	Future prospects	108-109
CHAPTER 3	Materials and Methods	110-125
3.1	Collection	110
3.2	Scientific classification of <i>Bambusa balcooa</i> Roxb.	110
3.3	Scientific classification of <i>Phyllanthus emblica</i> L. (syn. <i>Emblica officinalis</i>)	111
3.4	Scientific classification of <i>Hodgsonia heteroclita</i> (Roxb.) Hook.f. & Thomson	111
3.5	Scientific classification of <i>Punica granatum</i> L.	111-112
3.6	Authentication of plants	112
3.7	Preparation of the polyherbal formulation (PHF) and its naming	112
3.8	Preparation of PHF-HOPE extract	112
3.9	Determination of plant extract yield	112-113
3.10	Preliminary phytochemical screening	113-117
3.11	Microscopic study	117
3.12	Determination of physical characteristics of powder	117-118
3.13	Determination of the total phenolic content	118
3.14	Determination of the total flavonoid Content	118-119

Chapter	Description	Pages
3.15	DPPH radical scavenging activity	119-120
3.16	Reducing power assay	120
3.17	Hydrogen peroxide scavenging	120
3.18	Phytoconstituent profiling of PHF-HOPE extract by GC-MS/MS analysis	121
3.19	In vivo studies	121-125
3.20	Histopathology	125
CHAPTER 4	Results and Discussion	126-151
4.1	Plant materials	126
4.2	Yield of the extract	126
4.3	Organoleptic evaluation	126
4.4	Powder microscopy of PHF-HOPE	127
4.5	Determination of physical characteristics of powder	127-128
4.6	Heavy metal test	128
4.7	Preliminary phytochemical screening	128-131
4.8	Determination of biochemical constituents	131
4.9	Assessment of antioxidant activity	131-134
4.10	GC MS analysis	134-140
4.11	In vivo anti-hyperglycaemic activity	140-147
4.11	Histopathological studies	147-151
5	Conclusion	152-153
6	Bibliography	154-196
7	Appendix	A-D